# IDEXX: how the business works

> For learning only. Cityfort is not a registered investment adviser or broker-dealer and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

IDEXX Laboratories, Inc. · NASDAQ: IDXX · Sector: Health Care

Updated for Q3 FY2026 · checked Nov 20, 2026

This is the plain-text version of https://cityfort.co/stocks/idexx-laboratories. Source ids in [brackets] refer to the list at the end. Credit: "Cityfort, IDEXX: how the business works", with the page URL.

## The 30-second summary

IDEXX Laboratories makes the tests vets use to diagnose pets, and had revenue of $4.30 billion in FY2025. It places analyzers in clinics, then sells the test supplies, lab work and software those clinics keep buying; recurring diagnostics revenue was 79.2% of FY2025 revenue (Cityfort calculation from the FY2025 10-K). Vet clinics paid 91.9% of that revenue, while U.S. same-store clinical visits fell about 2% in 2025.

## 5 points

- **What it sells:** IDEXX sells in-clinic analyzers and their test supplies, rapid SNAP tests, reference lab testing, clinic software and water tests, with revenue of $4.30 billion in FY2025. [S4]
- **Who pays it:** In FY2025, vet clinics and hospitals paid 91.9% of IDEXX's revenue, water utilities and labs 4.7%, livestock, poultry and dairy customers 3.1% and human medical customers and licensees 0.4%; IDEXX discloses no single customer's share. [S4]
- **What it keeps from $100:** Of every $100 that came in during FY2025, IDEXX kept $24.6 as net income after $6.2 of income tax and $0.9 of interest; operating income, before interest and tax, was $1.36 billion. [S4]
- **Where the operating profit comes from:** The Companion Animal Group earned $1,265 million of FY2025 segment operating income, Water $93.3 million and Livestock, Poultry and Dairy $3.2 million. [S19]
- **The one thing to watch:** U.S. same-store clinical visits fell about 2% in 2025, while CAG Diagnostics recurring revenue grew 11% in Q3 FY2026. [S4, S16]

## What does IDEXX sell?

IDEXX makes the blood, urine and disease tests that vets use to find out what is wrong with a pet. It sells analyzers that sit in the clinic, the test supplies they use up, and testing in about 80 labs of its own. It also sells clinic software, X-ray systems, and tests for drinking water and farm animals.

- **In-clinic analyzers and their test supplies (IDEXX VetLab):** Machines such as Catalyst (blood chemistry), ProCyte (blood counts), SediVue (urine) and inVue Dx (cell samples) run tests during the visit. Their consumables brought in $1.50 billion in FY2025, against $200.2 million from selling the machines. [S4]
- **Reference lab testing:** Clinics send samples to about 80 IDEXX labs worldwide, with results the same or next day for most tests. Lab testing and consulting brought in $1.42 billion in FY2025. [S4]
- **Rapid tests (SNAP):** Single-use kits, such as SNAP 4Dx Plus, that a vet reads in minutes. They brought in $349.0 million in FY2025. [S4]
- **Clinic software and imaging:** Practice management software (Cornerstone, ezyVet, Animana, IDEXX Neo), digital X-ray systems (ImageVue) and the VetConnect PLUS results portal. This line brought in $345.9 million in FY2025. [S4]
- **Water tests:** Tests such as Colilert that water utilities and labs use to check for bacteria like E. coli. The Water segment brought in $201.1 million in FY2025. [S4]
- **Livestock, poultry and dairy tests:** Disease tests for cattle, pigs and poultry, and milk quality tests. This segment brought in $131.8 million in FY2025. [S4]

## Who pays IDEXX?

- **Veterinary clinics and hospitals (91.9% of revenue):** Pay for in-clinic tests, analyzers, lab testing, rapid tests and software (Companion Animal Group). [S4]
- **Water utilities and testing labs (4.7% of revenue):** Pay for drinking water and wastewater tests (Water segment). [S4]
- **Livestock, poultry and dairy producers and labs (3.1% of revenue):** Pay for animal disease and milk quality tests (LPD segment). [S4]
- **Human medical customers and licensees (0.4% of revenue):** Pay for human blood gas and electrolyte tests and for licensed technology (Other). [S4]
- **Customer concentration:** IDEXX does not disclose any single customer share of revenue. Its FY2025 10-K says vet clinics are consolidating into corporate hospital groups and buying groups. [S4]

## Where the money went (FY2025)

1. Vets, labs and water utilities paid IDEXX $4.30 billion of revenue in FY2025.
2. Making products and running its labs cost $1.64 billion, leaving $2.66 billion of gross profit.
3. Sales and marketing took $643.5 million, administration $404.8 million and research $251.2 million.
4. That left $1.36 billion of operating income; interest cost $38.9 million and interest earned added $3.0 million.
5. Income tax took $264.7 million, and $1.06 billion was left as net income.

Sources: S4.

## Key numbers by year (US$ million)

Financials: consolidated, US$ million. Fiscal years are the company's own: Fiscal year ends Dec 31 (the calendar year). — = not shown on the page.

| Year | Revenue | EBITDA | EBITDA margin | Net profit | Net margin | EPS (US$ per share, diluted) | Operating cash flow | Capital spending | Free cash flow | Sources |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| FY2021 | 3,215.4 | 1,036.6 | 32.2% | 744.8 | 23.2% | 8.6 | 755.5 | 119.5 | 636 | S14 |
| FY2022 | 3,367.3 | 1,010.7 | 30.0% | 679.1 | 20.2% | 8.03 | 543 | 148.8 | 394.1 | S13 |
| FY2023 | 3,661 | 1,212 | 33.1% | 845 | 23.1% | 10.06 | 906.5 | 133.6 | 772.9 | S12 |
| FY2024 | 3,897.5 | 1,258.3 | 32.3% | 887.9 | 22.8% | 10.67 | 929 | 120.9 | 808.1 | S8 |
| FY2025 | 4,303.7 | 1,505.2 | 35.0% | 1,059.5 | 24.6% | 13.08 | 1,181.8 | 124.7 | 1,057.1 | S4 |

- EBITDA here = operating income plus depreciation and amortization (from the cash flow statement).
- Net profit is the share belonging to the company's owners.

## Balance sheet (as of Sep 30, 2026, US$ million)

Net debt was $651.3 million at Sep 30, 2026, about 0.4 times FY2025 EBITDA of $1.51 billion (Cityfort calculation from the Q3 FY2026 10-Q and the FY2025 10-K). [S1, S4, S24]

| Item | Value |
| --- | --- |
| Total debt | 848.9 |
| Cash and investments | 197.5 |
| Net debt (debt minus cash) | 651.3 |
| Net worth (shareholders' money) | 1,869.2 |
| Debt to equity (times) | 0.45 |

- Total debt of $848.9 million is $474.0 million drawn on the credit facility plus $374.9 million of senior notes; minus $197.5 million of cash, that leaves net debt of $651.3 million (Cityfort calculation from the Q3 FY2026 10-Q).
- The $1.25 billion unsecured credit facility, signed Nov 13, 2025, includes a $250.0 million term loan due Nov 12, 2028; $773.2 million was still available at Sep 30, 2026.
- The senior notes are private placements: $75 million at 3.72% due Feb 12, 2027, $100 million at 4.19% due 2029 and $200 million at 2.50% due 2030. IDEXX repaid another $75 million of 3.72% notes on Sep 4, 2026.
- The only financial covenant caps debt at 3.5 times adjusted EBITDA; the 10-Q says IDEXX was in compliance.
- Goodwill rose from $414.0 million at Dec 31, 2025 to $640.5 million at Sep 30, 2026, a period that included the CoVet purchase. Debt here leaves out lease liabilities.

## Who owns IDEXX? (as of Mar 8, 2026)

Each share has one vote, and the proxy names no holder above 5% other than Vanguard (12.20%) and BlackRock (9.56%). The 20 directors and executive officers together owned 179,255 shares, about 0.2% of the 79.5 million shares at Mar 8, 2026 (Cityfort calculation from the 2026 proxy statement). [S15, S1]

- Officers and directors (as a group), shares: 0.2%

| Class | Shares (millions) | Votes per share | % of shares | % of votes | Traded | Sources |
| --- | --- | --- | --- | --- | --- | --- |
| Common stock (78.79 million shares at Sep 30, 2026 (Q3 FY2026 10-Q). It is the only class of stock.) | 78.79 | 1 | — | — | Yes | S1 |

Holders of 5% or more (each row shows the date of its own filing):

| Holder | Shares | Votes | As of | Note | Sources |
| --- | --- | --- | --- | --- | --- |
| The Vanguard Group | 12.2% | — | Nov 12, 2024 | Proxy figure from a Schedule 13G/A filed Nov 12, 2024 (9,703,237 shares at Sep 30, 2024). Vanguard also keeps the records for IDEXX's 401(k) plan. | S15 |
| BlackRock, Inc. | 9.56% | — | Apr 17, 2025 | Proxy figure from a Schedule 13G/A filed Apr 17, 2025 (7,599,078 shares at Mar 31, 2025). | S15 |

## What could go wrong

### Rivals with deep pockets

Mars (Antech, Heska) and Zoetis compete in pet lab tests and in-clinic analyzers. The 10-K says some rivals have greater financial resources and expects competition to grow, including from AI. [S4]

What to watch: CAG Diagnostics recurring revenue growth each quarter.

### Fewer pet visits to vets

U.S. same-store clinical visits fell about 2% in 2025. The 10-K says economic weakness could lead pet owners to skip or delay vet visits. [S4]

What to watch: U.S. clinical visit trends in each earnings release.

### Clinics joining large groups

The 10-K says U.S. vet clinics are consolidating under corporate owners and buying groups. It says decisions by these larger buyers could hurt IDEXX profits. [S4]

What to watch: Any loss or gain of a corporate hospital group contract.

### One supplier for chemistry slides

Ortho-Clinical Diagnostics is the sole source of certain Catalyst chemistry slides. The 10-K says some sole-source products cannot be readily replaced. [S4, S2]

What to watch: Changes to the Ortho supply agreements (amendments effective May 19, 2026 were filed with the Q2 FY2026 10-Q).

### Sales outside the U.S. and currency swings

About 36% of FY2025 revenue came from outside the U.S., including 81% of LPD revenue. Currency moves change reported results, and trade or political events can disrupt sales. [S4]

What to watch: The gap between reported and organic growth.

### New CEO and an AI purchase

Mike Erickson became CEO on May 12, 2026, and IDEXX bought CoVet for about $250 million in September 2026. IDEXX said its lowered FY2026 operating margin outlook includes the impact of acquisitions. [S16, S1]

What to watch: Operating margin against the 32.1% to 32.3% FY2026 range.

### Cyberattacks and AI errors

The 10-K says IDEXX and some of its vendors have faced cyberattacks, none with a material impact to its knowledge. It also warns that AI built into its products could cause harm to its reputation or legal liability. [S4]

What to watch: Any cyber incident disclosed in an 8-K or 10-Q.

## What to watch

Next: Q4 FY2026 results, Date not announced yet.

- **Results against the FY2026 range:** IDEXX said on Nov 2, 2026 that it expects FY2026 revenue of $4,741 million to $4,767 million and EPS of $14.96 to $15.16. FY2025 revenue was $4.30 billion and EPS was $13.08.
- **Pet visits against repeat testing:** U.S. same-store clinical visits fell about 2% in 2025. CAG Diagnostics recurring revenue grew 11% in Q3 FY2026.
- **inVue Dx placements:** IDEXX placed over 1,900 inVue Dx analyzers in Q3 FY2026, bringing the installed base to nearly 11,000.
- **Operating margin after the CoVet purchase:** IDEXX bought CoVet for about $250 million in September 2026. On Nov 2, 2026 it lowered its FY2026 operating margin range from 32.3% to 32.5% (given Aug 4, 2026) to 32.1% to 32.3%, including acquisition impacts.

## Sources

- S1: Form 10-Q for Q3 FY2026. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/874716/000087471626000135/0000874716-26-000135-index.htm (published Nov 2, 2026)
- S2: Form 10-Q for Q2 FY2026. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/874716/000087471626000123/0000874716-26-000123-index.htm (published Aug 4, 2026)
- S3: Form 10-Q for Q1 FY2026. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/874716/000087471626000076/0000874716-26-000076-index.htm (published May 5, 2026)
- S4: Form 10-K for FY2025. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/874716/000087471626000038/0000874716-26-000038-index.htm (published Feb 20, 2026)
- S5: Form 10-Q for Q3 FY2025. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/874716/000087471625000165/0000874716-25-000165-index.htm (published Nov 3, 2025)
- S6: Form 10-Q for Q2 FY2025. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/874716/000087471625000121/0000874716-25-000121-index.htm (published Aug 4, 2025)
- S7: Form 10-Q for Q1 FY2025. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/874716/000087471625000062/0000874716-25-000062-index.htm (published May 1, 2025)
- S8: Form 10-K for FY2024. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/874716/000087471625000037/0000874716-25-000037-index.htm (published Feb 21, 2025)
- S9: Form 10-Q for Q3 FY2024. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/874716/000087471624000139/0000874716-24-000139-index.htm (published Oct 31, 2024)
- S10: Form 10-Q for Q2 FY2024. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/874716/000087471624000121/0000874716-24-000121-index.htm (published Aug 6, 2024)
- S11: Form 10-Q for Q1 FY2024. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/874716/000087471624000083/0000874716-24-000083-index.htm (published May 1, 2024)
- S12: Form 10-K for FY2023. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/874716/000087471624000057/0000874716-24-000057-index.htm (published Feb 22, 2024)
- S13: Form 10-K for FY2022. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/874716/000087471623000006/0000874716-23-000006-index.htm (published Feb 16, 2023)
- S14: Form 10-K for FY2021. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/874716/000087471622000007/0000874716-22-000007-index.htm (published Feb 16, 2022)
- S15: 2026 proxy statement (DEF 14A). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/874716/000087471626000064/idxx-20260327.htm (published Mar 27, 2026)
- S16: Q3 FY2026 earnings release (8-K Exhibit 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/874716/000110465926120892/tm2628647d1_ex99-1.htm (published Nov 2, 2026)
- S17: Q2 FY2026 earnings release (8-K Exhibit 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/874716/000110465926090033/tm2622041d1_ex99-1.htm (published Aug 4, 2026)
- S18: Q1 FY2026 earnings release (8-K Exhibit 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/874716/000110465926055203/tm2613510d1_ex99-1.htm (published May 5, 2026)
- S19: Q4 FY2025 earnings release (8-K Exhibit 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/874716/000110465926008904/tm264623d1_ex99-1.htm (published Feb 2, 2026)
- S20: Q3 FY2025 earnings release (8-K Exhibit 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/874716/000110465925105185/tm2530045d1_ex99-1.htm (published Nov 3, 2025)
- S21: Q2 FY2025 earnings release (8-K Exhibit 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/874716/000110465925073304/tm2522386d1_ex99-1.htm (published Aug 4, 2025)
- S22: Q1 FY2025 earnings release (8-K Exhibit 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/874716/000110465925042955/tm2513742d1_ex99-1.htm (published May 1, 2025)
- S23: Q4 FY2024 earnings release (8-K Exhibit 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/874716/000110465925008331/tm255269d1_ex99-1.htm (published Feb 3, 2025)
- S24: Credit agreement, 8-K Exhibit 10.1 filed Nov 13, 2025. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/874716/000110465925111278/tm2530872d1_ex10-1.htm (published Nov 13, 2025)
- S25: CEO transition announcement, 8-K Exhibit 99.1 filed Jan 13, 2026. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/874716/000110465926003103/tm262817d1_ex99-1.htm (published Jan 13, 2026)
- S26: Share repurchase authorization, 8-K Exhibit 99.1 filed Dec 9, 2024. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/874716/000087471624000148/ex991-idxxsharerepurchase.htm (published Dec 9, 2024)
- S27: Director retirement, 8-K Item 5.02 filed Feb 13, 2026. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/874716/000087471626000007/idxx-20260213.htm (published Feb 13, 2026)
